We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.875 | 2.75 | 3.00 | 2.975 | 2.875 | 2.875 | 320,409 | 08:00:06 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.19 | 136.8M |
From May 2021 to May 2024
By Sabela Ojea
Allergy Therapeutics PLC said that it has received clearance for an investigational new drug application from the U.S. Food & Drug Administration for its peanut allergy vaccine.
The commercial biotechnology company specializing in allergy vaccines said this clearance paves the way for the first phase Protect trial, to be launched in the U.S.
The trial will begin later this year, Chief Executive Manuel Llobet said.
Shares at 0802 GMT were up 1.50 pence, or 6.3%, at 25.25 pence.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 26, 2022 03:30 ET (08:30 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Allergy Therapeutics Chart |
1 Month Allergy Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
